Skip to main content

Genetic Diseases

0
Pipeline Programs
5
Companies
8
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
3 programs
3-year follow-upN/A1 trial
Genomic sequencing and molecular diagnostic results, if any.N/A1 trial
Microarray analysisN/A1 trial
Active Trials
NCT02160938Completed184Est. Dec 2018
NCT03211039Unknown213Est. Jul 2024
NCT01279733Completed4,450Est. Oct 2011
Genomics
GenomicsUK - Oxford
3 programs
Genomic sequencing and molecular diagnostic results, if anyN/A1 trial
Genomic sequencing and molecular diagnostic results, if anyN/A1 trial
Genomic sequencing and molecular diagnostic results, if any.N/A
Active Trials
NCT03385876Enrolling By Invitation100,000Est. Dec 2050
NCT02917460Recruiting102,000Est. Dec 2050
Genome & Company
Genome & CompanyKorea - Suwon
2 programs
3-year follow-upN/A
Genomic sequencing and molecular diagnostic results, if any.N/A
Imagine Pharma
Imagine PharmaPA - Pittsburgh
2 programs
Biological SamplesN/A1 trial
Whole genome sequencing and Genome-Epigenome-Phenome AssociationsN/A1 trial
Active Trials
NCT06235580Recruiting1,000Est. Dec 2035
NCT06260319Completed720Est. Jan 2024
Eloxx Pharmaceuticals
1 program
ELX-02PHASE_11 trial
Active Trials
NCT02807961Terminated42Est. May 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Eloxx PharmaceuticalsELX-02
Imagine PharmaWhole genome sequencing and Genome-Epigenome-Phenome Associations
GenomicsGenomic sequencing and molecular diagnostic results, if any
Human BioSciencesGenomic sequencing and molecular diagnostic results, if any.
GenomicsGenomic sequencing and molecular diagnostic results, if any
Imagine PharmaBiological Samples
Human BioSciences3-year follow-up
Human BioSciencesMicroarray analysis

Clinical Trials (8)

Total enrollment: 208,609 patients across 8 trials

NCT02807961Eloxx PharmaceuticalsELX-02

Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Start: Jul 2016Est. completion: May 201742 patients
Phase 1Terminated
NCT06260319Imagine PharmaWhole genome sequencing and Genome-Epigenome-Phenome Associations

Decoding Developmental Disorders in Humams

Start: Jan 2019Est. completion: Jan 2024720 patients
N/ACompleted
NCT03385876GenomicsGenomic sequencing and molecular diagnostic results, if any

Rapid Whole Genome Sequencing Study

Start: Aug 2017Est. completion: Dec 2050100,000 patients
N/AEnrolling By Invitation
NCT03211039Human BioSciencesGenomic sequencing and molecular diagnostic results, if any.

Perinatal Precision Medicine

Start: Jun 2017Est. completion: Jul 2024213 patients
N/AUnknown
NCT02917460GenomicsGenomic sequencing and molecular diagnostic results, if any

Rady Children's Institute Genomic Biorepository

Start: Jul 2016Est. completion: Dec 2050102,000 patients
N/ARecruiting
NCT06235580Imagine PharmaBiological Samples

Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions

Start: Dec 2015Est. completion: Dec 20351,000 patients
N/ARecruiting
NCT02160938Human BioSciences3-year follow-up

Prenatal Microarray Follow-Up Study

Start: Feb 2013Est. completion: Dec 2018184 patients
N/ACompleted
NCT01279733Human BioSciencesMicroarray analysis

Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis

Start: Oct 2008Est. completion: Oct 20114,450 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 208,609 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.